Repeated lipopolysaccharide (LPS) exposure inhibits HIV replication in primary human macrophages

Microbes and Infection

Volumn 8, Issue 9-10, 2006, Pages 2469-2476

  Equils, Ozlem ^a,b   Salehi, Ken Khosrowdad ^b,c   Cornataeanu, Randall ^a   Lu, Daning ^a,b   Singh, Sapna ^a   Whittaker, Katherine ^b,c   Baldwin, Gayle Cocita ^b,c  

^a Steven Spielberg Pediatric Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cross tolerance; HIV; HIV 1; HIV LTR; Lipopolysaccharide; Macrophages; NF B; Opportunistic infection; Phenol soluble modulin; Reprogramming; Tolerance

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LUCIFERASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; VIRUS REPLICATION;

BACTERIAL TOXINS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL DEATH; CELL LINE; ESCHERICHIA COLI; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LUCIFERASES; MACROPHAGES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANS-ACTIVATION (GENETICS); TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 33749463278     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.06.002     Document Type: Article

References (64)

1. Ziegler-Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 45 (1995) 13-26
2. Wysocka M., Robertson S., Riemann H., Caamano J., Hunter C., Mackiewicz A., Montaner L.J., Trinchieri G., and Karp C.L. IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J. Immunol. 166 (2001) 7504-7513
3. Wittmann M., Larsson V.A., Schmidt P., Begemann G., Kapp A., and Wefel T. Suppression of interleukin-12 production by human monocytes after preincubation with lipopolysaccharide. Blood 94 (1999) 1717-1726
4. Beeson P.B. Tolerance to bacterial pyrogens: factors influencing its development. J. Exp. Med. 86 (1947) 29-38
5. Hass J.G., Baeuerle P.A., Riethmuller G., and Ziegler-Heitbrock H.W. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc. Natl. Acad. Sci. USA 87 (1990) 9563-9567
6. Ziegler-Heitbrock H.W. In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology (1992) 75-264-8
7. Virca G.D., Kim S.Y., Glaser K.B., and Ulevitch R.J. Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. Boil Chem. 264 (1989) 21951-21956
8. Zuckerman S.H., Evans G.F., Snyder Y.M., and Roeder W.D. Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J. Immunol. 143 (1989) 1223-1227
9. Granowitz E.V., Porat R., Mier J.W., Orencole S.F., Kaplanski G., Lynch E.A., Ye K., Vannier E., Wolff S.M., and Dinarello C.A. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J. Immunol. 151 (1993) 1637-1645
10. Munoz C., Carlet J., Fitting C., Misset B., Bleriot J.P., and Cavaillon J.M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88 (1991) 1747-1754
11. Equils O., Schito M.L., Karahashi H., Madak Z., Yarali A., Michelsen K.S., Sher A., and Arditi M. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170 (2003) 5159-5164
12. Bafica A., Scanga C.A., Equils O., and Sher A. The induction of Toll-like receptor tolerance enhances rather than suppresses HIV-1 gene expression in transgenic mice. J. Leukoc. Biol. 75 (2004) 460-466
13. Jamieson B.D., and Zack J.A. Murine models for HIV disease. AIDS 13 Suppl. A (1999) S5-S11
14. Mehlin C., Headley C.M., and Klebanoff S.J. An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J. Exp. Med. 189 (1999) 907-918
15. McIntire F.C., Sievert H.W., Barlow G.H., Finley R.A., and Lee A.Y. Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry 6 (1967) 2363-2372
16. Ibarrondo F.J., Choi R., Geng Y.Z., Canon J., Rey O., Baldwin G.C., and Krogstad P. HIV type 1 Gag and nucleocapsid proteins: cytoskeletal localization and effects on cell motility. AIDS Res. Hum. Retroviruses 17 (2001) 1489-1500
17. LaRue K.E., and McCall C.E. A labile transcriptional repressor modulates endotoxin tolerance. J. Exp. Med. 180 (1994) 2269-2275
18. Medvedev A.E., Kopydlowski K.M., and Vogel S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J. Immunol. 164 (2000) 5564-5574
19. Henricson B.E., Neta R., and Vogel S.N. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect. Immun. 59 (1991) 1188
20. Sato S., Nomura F., Kawai T., Takeuchi O., Muhlradt P.F., Takeda K., and Akira S. Synergy and cross-tolerance between Toll-like receptor (TLR)2- and TLR4-mediated signaling pathways. J. Immunol. 165 (2000) 7096
21. Lehner M.D., Morath S., Michelsen K.S., Schumann R.R., and Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J. Immunol. 166 (2001) 5161
22. Virca G.D., Kim S.Y., Glaser K.B., and Ulevitch R.J. Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. J. Biol. Chem. 264 (1989) 21951
23. Dobrovolskaia M.A., Medvedev A.E., Thomas K.E., Cuesta N., Toshchakov V., Ren T., Cody M.J., Michalek S.M., Rice N.R., and Vogel S.N. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J. Immunol. 170 (2003) 508-519
24. Van der Kleij D., Van den Biggelaar A.H., Kruize Y.C., Retra K., Fillie Y., Schmitz M., Kremsner P.G., Tielens A.G., and Yazdanbakhsh M. Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J. Infect. Dis. 189 (2004) 1044-1051
25. Peck O.M., Fan H., Tempel G.E., Teti G., Halushka P.V., and Cook J.A. Staphylococcus aureus and lipopolysaccharide induce homologous tolerance but heterologous priming: role of interferon-gamma. Shock 21 (2004) 254-260
26. Kilmartin B., and Reen D.J. HSP60 induces self-tolerance to repeated HSP60 stimulation and cross-tolerance to other pro-inflammatory stimuli. Eur. J. Immunol. 34 (2004) 2041-2051
27. Akira S., Isshiki H., Sugita T., Tanabe O., Kinoshita S., Nishio Y., Nakajima T., Hirano T., and Kishimoto T. A nuclear factor for IL-6 expression (NF-IL6). EMBO J. 9 (1990) 1897-1906
28. Natsuka S., and Akira S. Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin 6. Blood 79 (1992) 460-466
29. Liu H., Sidiropoulos P., Song G., Pagliari L.J., Birrer M.J., Stein B., Anrather J., and Pope R.M. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J. Immunol. 164 (2000) 4277-4285
30. Henderson A.J., Connor R.I., and Calame K.L. C/EBP activators are required for HIV-1 replication and proviral induction in monocytic cell lines. Immunity 5 (1996) 91-101
31. +T cells. Proc. Natl. Acad. Sci. USA 94 (1997) 8714-8719
32. Bernstein M.S., Tong-Starksen S.E., and Locksley R.M. Activation of human monocyte-derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication at the level of gene expression. J. Clin. Invest. 88 (1991) 540-545
33. Tesmer V.M., Rajadhyaksha A., Babin J., and Bina M. NF IL-6-mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90 (1993) 72980-77302
34. Fauci A.S. AIDS: immunopathogenic mechanisms and research strategies. Clin. Res. 35 (1987) 503-510
35. Kedzierska K., and Crowe S.M. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr. Med. Chem. 9 (2002) 1893-1903
36. Poli G., and Fauci A.S. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. Human Cytokines: Their Role in Disease and Therapy 421 (1995), Blackwell, Cambridge
37. Barbaro G., Di Lorenzo G., Soldini M., Giancaspro G., Grisorio B., Pellicelli A., and Barbarini G. The intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 100 (1999) 933-939
38. Tyor W.R., Glass J.D., Griffin J.W., Becker P.S., McArthur J.C., Bezman L., and Griffin D.E. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann. Neurol. 3 (1992) 349-360
39. Pulliam L., Herndier B.G., Tang N.M., and McGrath M.S. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J. Clin. Invest. 87 (1991) 503-512
40. Grunfeld C., and Feingold K.R. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N. Engl. J. Med. 327 (1992) 329-337
41. McGowan I., Radford-Smith G., and Jewell D.P. Cytokine gene expression in HIV-infected intestinal mucosa. AIDS 8 (1994) 1569-1575
42. Wittmann M., Larsson V.A., Schmidt P., Begemann G., Kapp A., and Werfel T. Suppression of interleukin-12 production by human monocytes after preincubation with lipopolysaccharide. Blood 94 (1999) 1717-1726
43. Ziegler-Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 45 (1995) 13-26
44. Duh E.J., Maury W.J., Folks T.M., Fauci A.S., and Rabson A.B. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86 (1989) 5974
45. Griffin G.E., Leung K., Folks T.M., Kunkel S., and Nabel G.J. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 339 (1989) 70
46. Mellors J., Griffith B., Ortiz M., Landy M., and Ryan J. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J. Infect. Dis. 163 (1991) 78
47. Coffey M., Woffendin C., Phare S., Strieter R., and Markovitz D. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am. J. Physiol. 272 (1997) L1025
48. Moriuchi H., Moriuchi M., and Fauci A. Nuclear factor-κB potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J. Immunol. 158 (1997) 3483
49. Herbein G., Montaner L., and Gorden S. Tumor necrosis factor α inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J. Virol. 70 (1996) 7388
50. Herbein G., and Gordon S. 55- and 75-kilodalton tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. J. Virol. 71 (1997) 4150
51. Khoo S., Pepper L., Snowden N., Hajeer A., Vallely P., Wilkins E., Mandal B., and Ollier W. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 11 (1997) 423
52. West M.A., LeMieur T., Clair L., Bellingham J., and Rodriguez J.L. Protein kinase C regulates macrophage tumor necrosis factor secretion: direct protein kinase C activation restores tumor necrosis factor production in endotoxin tolerance. Surgery 122 (1997) 204-211 discussion 211-2
53. Bowling W.M., Hafenrichter D.G., Flye M.W., and Callery M.P. Endotoxin tolerance alters phospholipase C-gamma 1 and phosphatidylinositol-3′-kinase expression in peritoneal macrophages. J. Surg. Res. 58 (1995) 592-598
54. Tominaga K., Saito S., Matsuura M., and Nakano M. Lipopolysaccharide tolerance in murine peritoneal macrophages induces downregulation of the lipopolysaccharide signal transduction pathway through mitogen-activated protein kinase and nuclear factor-kappaB cascades, but not lipopolysaccharide-incorporation steps. Biochim. Biophys. Acta 1450 (1999) 130-144
55. Kohler N.G., and Joly A. The involvement of an LPS inducible I kappa B kinase in endotoxin tolerance. Biochem. Biophys. Res. Commun. 232 (1997) 602-607
56. Medvedev A.E., Kopydlowski K.M., and Vogel S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J. Immunol. 164 (2000) 5564-5574
57. Ziegler-Heitbrock H.W., Wedel A., Schraut W., Strobel M., Wendelgass P., Sternsdorf T., Bauerle P.A., Haas J.G., and Riethmuller G. Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50homodimers. J. Biol. Chem. 269 (1994) 17001-17004
58. Kastenbauer S., and Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect. Immun. 67 (1999) 1553-1559
59. Medvedev A.E., Lentschat A., Wahl L.M., Golenbock D.T., and Vogel S.N. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J. Immunol. 169 (2002) 5209-5216
60. Martin M., Katz J., Vogel S.N., and Michalek S.M. Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. J. Immunol. 167 (2001) 5278
61. Fahmi H., Ancuta P., Perrier S., and Chaby R. Preexposure of mouse peritoneal macrophages to lipopolysaccharide and other stimuli enhances the nitric oxide response to secondary stimuli. Inflamm. Res. 45 (1996) 347-353
62. Diterich I., Rauter C., Kirschning C.J., and Hartung T. Burgdorferi-induced tolerance as a model of persistence via immunosuppression. Infect. Immun. 71 (2003) 3979-3987
63. Nakayama K., Okugawa S., Yanagimoto S., Kitazawa T., Tsukada K., Kawada M., Kimura S., Hirai K., Takagaki Y., and Ota Y. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J. Biol. Chem. 279 (2004) 6629-6634
64. Fichtenbaum C.J., Dunagan W.C., and Powderly W.G. Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8 (1995) 51-57